DGCI approves Sputnik V, fast-growing vaccine in India:
The Drugs Controller General of India (DGCI) has approves a Pune-based serum company to produce the Russian vaccine Sputnik V vaccine, a fast-growing vaccine in India. The vaccine has already reached India in two installments. The serum company has recently applied to the DGCI to allow them to manufacture it in India. The DGCI has suggested that the vaccine be tested, analyzed, and started production.
The serum company has entered into an agreement with the Russian company Gamaleya Research Institute of Epidemiology and Microbiology for the production of this vaccine. Oxford Astrazeneca, a serum company already under the auspices of Adar Poonawalla, is already making the vaccine domestically under the name Covshield vaccine.
The company has assured the Indian government that it will deliver 10 crore doses of the vaccine this June. Although the same company is also manufacturing the Novavox vaccine, it needs to get the green signal from the US regulatory body. Sources said the company had recently sent an application to the US regulatory body for the permit. In the meantime, Prime Minister Modi visited various vaccine manufacturers and sought to increase production further.
However, changes in the center’s liberalized policy have resulted in a shortage of vaccines. A new problem has arisen with the adoption of different pricing policies regarding the vaccine. There has been a delay in vaccinating people between the ages of 18-44. Meanwhile, Dr. Reddy’s Lab in Hyderabad has entered into an agreement with the Russian Direct Investment Fund for the sale of 250 million doses of the Sputnik V vaccine in India.
Telangana Corona Emergency Contact Information:
For Free Ambulance (Cyberabad)
For Free cab Services (Rachakonda)